Alpha emitters are radioactive particles that are useful in the treatment of various cancers. They work by emitting high-energy alpha particles that can destroy targeted cancerous cells from within while causing minimal harm to surrounding healthy tissues. Ra-223 dichloride is one such alpha emitter approved for the treatment of castration-resistant prostate cancer. Researchers are exploring the use of various other alpha emitter-based radiotherapies for cancers of the liver, brain, and bone.

The global Alpha Emitter Market is estimated to be valued at US$ 1331 million in 2023 and is expected to exhibit a CAGR of 16% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:

The expanding applications of alpha emitters in cancer treatment is one of the key trends driving the growth of the alpha emitter market. Based on promising results from ongoing clinical trials, regulators are expected to approve additional alpha emitter-based radiotherapies to treat several hard-to-treat cancers in the coming years. This will significantly increase the adoption of alpha emitters among healthcare facilities. Furthermore, as alpha emitters allow targeted radiation therapy while minimizing toxicity, their demand is expected to rise as cancer cases continue to surge worldwide. Continuous research focusing on improving the selectivity and efficacy alpha emitter-based cancer treatments augurs well for the long-term prospects of this market.

Segment Analysis

The global alpha emitter market is dominated by diagnostic segment, which accounted for around 65% share of the overall market in 2023. The diagnostic segment utilize alpha emitters like radium 223 for bone metastases treatment and actinium 225 attached to monoclonal antibodies (mAbs) for targeted alpha therapy for cancer treatment. These applications have driven the growth of diagnostic segment over other segments such as therapeutic.

Key Takeaways

The Global Alpha Emitter Market Size is estimated to be valued at US$ 1331 million in 2023 and is expected to exhibit a CAGR of 16% over the forecast period 2023 to 2030.

North America accounted for the largest share of around 40% of the overall alpha emitter market in 2023. The region leads in adoption of targeted alpha therapy for cancer treatment. Growing research in the field is also driving the North America market. Asia Pacific is expected to witness highest growth during the forecast period owing to improving healthcare infrastructure and increasing healthcare spending in emerging economies of the region.

Key players: Key players operating in the alpha emitter market are Abbott, BD, Cardinal Health, Johnson & Johnson, Medtronic, 3M, Steris, Teleflex. Abbott leads the market owing to strong portfolio of brachytherapy devices and seeds offering alpha emitting isotopes like iodine-125 and palladium-103 for radiation synovectomy. 3M is another leading player driven by wide gamma of products including soft tissue markers enabled with alpha emitting isotope like gold-198.

Get More Insights Here

https://healthcarelatesteditionnews.blogspot.com/2023/12/the-global-alpha-emitter-market-growth.html